Q-omics provides the consensus-scored TTC39A profile across patient tissues and cancer cell-line models. TTC39A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TTC39A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TTC39A protein abundance shows 21,541 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and KIRC as cancer lineages where TTC39A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC39A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC39A survival associations across molecular data types. TTC39A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC39A RNA expression–survival associations across cancer types. High TTC39A expression shows unfavorable associations in LGG, SKCM and UVM, but favorable associations in BRCA, ACC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TTC39A RNA expression.
This table summarizes TTC39A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC39A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC39A shows lower tumor expression in HNSC and higher tumor expression in KIRC, KIRP, LIHC, BLCA and THCA. The KIRC box plot shows higher TTC39A RNA expression in tumor versus normal tissue (log2 FC = +2.485, t-test p < 0.001).
This table shows molecular features associated with TTC39A in patient tissues and cancer cell lines. In patient samples, TTC39A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC39A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
